New follow-up phase III data reinforce the long-term benefit of Roche ’s Hemlibra for people with haemophilia A
Basel, 7 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a new analysis of pooled, three-year follow-up data of 401 people with haemophilia A from the pivotal HAVEN 1-4 studies, which reinforce the long-term efficacy and safety profile of Hemlibra ® (emicizumab).[1]These data, from adults, adolescents and children with haemophilia A with and without factor VIII inhibitors, were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 5-8 December 2020.“The long-term benefit of Hemlibra, with a consistent safety profile and durably effective con...
Source: Roche Media News - December 7, 2020 Category: Pharmaceuticals Source Type: news
New follow-up phase III data reinforce the long-term benefit of Roche ’s Hemlibra for people with haemophilia A
Basel, 7 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a new analysis of pooled, three-year follow-up data of 401 people with haemophilia A from the pivotal HAVEN 1-4 studies, which reinforce the long-term efficacy and safety profile of Hemlibra ® (emicizumab).[1]These data, from adults, adolescents and children with haemophilia A with and without factor VIII inhibitors, were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 5-8 December 2020.“The long-term benefit of Hemlibra, with a consistent safety profile and durably effective con...
Source: Roche Investor Update - December 7, 2020 Category: Pharmaceuticals Source Type: news
On World AIDS Day, Those Who Fought the 1980s Epidemic Find Striking Differences and Tragic Parallels in COVID-19
More than three decades after the World Health Organization (WHO) launched the first World AIDS Day on Dec. 1, 1988, the world’s leading global health organization faces another public health crisis in COVID-19. On this World AIDS Day, those who raised awareness of HIV, the virus that causes AIDS, find devastating similarities and haunting differences in America’s response to both crises.
In 1981, scientists recorded the first cases of a rare pneumonia, usually found among immunosuppressed patients, among a group of gay men in Los Angeles, and noticed more cases appearing among gay men in San Francisco and New ...
Source: TIME: Health - December 1, 2020 Category: Consumer Health News Authors: Olivia B. Waxman Tags: Uncategorized COVID-19 feature HIV/AIDS Source Type: news
Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
Basel, 5 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth o f Roche’s haematology portfolio and pipeline, and commitment to developing...
Source: Roche Media News - November 5, 2020 Category: Pharmaceuticals Source Type: news
Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
Basel, 5 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth o f Roche’s haematology portfolio and pipeline, and commitment to developing...
Source: Roche Investor Update - November 5, 2020 Category: Pharmaceuticals Source Type: news
Post-Dental Extraction Bleeding Decreases With Mouth Splints Post-Dental Extraction Bleeding Decreases With Mouth Splints
Dental extractions can cause significant risk of bleeding in patients with hemophilia being treated with factor replacements.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 4, 2020 Category: Cancer & Oncology Tags: Dental & Oral Health News Source Type: news
PHARMAC funding emicizumab for severe haemophilia A
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2020 Category: Drugs & Pharmacology Source Type: news
26.10.20: Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapy
Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapyAcquisition fuels Bayer's cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need / AskBio's industry leading AAV-based gene therapy platform already yielding commercial and clinical stage assets with potential of helping larger patient populations / Portfolio includes investigational pre-clinical and clinical stage development candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases such as ...
Source: Bayer IR Newsfeed: Events - October 26, 2020 Category: Pharmaceuticals Source Type: news
Bayer-acquires-Asklepios-BioPharmaceutical-to-broaden-innovation-base-in-cell-and-gene-therapy
Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need / AskBio's industry leading AAV-based gene therapy platform already yielding commercial and clinical stage assets with potential of helping larger patient populations / Portfolio includes investigational pre-clinical and clinical stage development candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases such as therapeutics for Pompe disease, Parkinson’s disease and congestive heart failure, ...
Source: Bayer Company News - October 26, 2020 Category: Pharmaceuticals Source Type: news
Disregarding Rights of Persons with Disabilities
The focus of the International Day of Persons with Disabilities, which falls on 3 December, is the link between the empowerment of people living with disability, and the 2030 Agenda for Sustainable Development, the UN’s blueprint for a better future for people and the planet. Credit: UN NewsBy Shudarson Subedi and Simone GalimbertiKATHMANDU, Nepal, Oct 15 2020 (IPS) The lack of consistency and a patchy approach undermines the Government of Nepal’s credibility in fulfilling the rights of persons with disabilities. One step forward and several steps back.
If we want to describe the current progress being made by the Gov...
Source: IPS Inter Press Service - Health - October 15, 2020 Category: International Medicine & Public Health Authors: Shudarson Subedi and Simone Galimberti Tags: Asia-Pacific Development & Aid Featured Global Headlines Health Human Rights IPS UN: Inside the Glasshouse Population TerraViva United Nations Source Type: news
Early Trial Offers New Hope for People With Hemophilia
Title: Early Trial Offers New Hope for People With HemophiliaCategory: Health NewsCreated: 9/9/2020 12:00:00 AMLast Editorial Review: 9/10/2020 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - September 10, 2020 Category: Anesthesiology Source Type: news
Early Trial Offers New Hope for People With Hemophilia
WEDNESDAY, Sept. 9, 2020 -- Researchers may have found a way for people with severe hemophilia to take their standard treatment less often, if the results of an early trial pan out.
In what experts called a feat of bioengineering, scientists were... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 9, 2020 Category: General Medicine Source Type: news
Are new treatments for haemophilia A value for money?
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 31, 2020 Category: Drugs & Pharmacology Source Type: news
Paying for cell and gene therapy - Is the future already here?
The ascent of cell and gene therapies over the past few years has been astonishing. And their rise looks unstoppable: By 2025, the FDA expects it will be reviewing 10 to 20 of these transformative drugs per year.
But as we listen to affordability concerns from payers, providers and patients, we ’ve also had to ask, perhaps a bit provocatively, how we can afford to pay for this boom in future cures? " Without solutions to help payers manage the cost, some of our members may make the choice to exclude coverage " , stated insurer CVS Health earlier in the year in its position paper on gene therapy. “Some plans ar...
Source: EyeForPharma - August 25, 2020 Category: Pharmaceuticals Authors: Ulrich Neumann Source Type: news
Paying for cell and gene therapy - Is the future already here?
The ascent of cell and gene therapies over the past few years has been astonishing. And their rise looks unstoppable: By 2025, the FDA expects it will be reviewing 10 to 20 of these transformative drugs per year.
But as we listen to affordability concerns from payers, providers and patients, we ’ve also had to ask, perhaps a bit provocatively, how we can afford to pay for this boom in future cures? " Without solutions to help payers manage the cost, some of our members may make the choice to exclude coverage " , stated insurer CVS Health earlier in the year in its position paper on gene therapy. “Some plans ar...
Source: EyeForPharma - August 25, 2020 Category: Pharmaceuticals Authors: Ulrich Neumann Source Type: news
